Trial Profile
Multicenter Phase II Study of Nivolumab in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 16 Aug 2019 Status changed from active, no longer recruiting to completed.
- 27 Mar 2018 Results of exploratory analysis investigating the clinical significance of PD-L1, HLA-A, and HLA-B expression in nasopharyngeal carcinoma tumors and plasma EBV DNA published in the Journal of Clinical Oncology
- 05 Oct 2016 Status changed from suspended to active, no longer recruiting.